Trials / Completed
CompletedNCT03140631
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation: A Randomized Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- University of Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety, efficacy and efficiency of rapid anticoagulation reversal with protamine sulfate versus routine activated clotting time (ACT) monitoring in patients undergoing catheter based ablation of atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Protamine Sulfate | Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects. |
Timeline
- Start date
- 2017-03-23
- Primary completion
- 2017-11-16
- Completion
- 2018-04-03
- First posted
- 2017-05-04
- Last updated
- 2018-10-23
- Results posted
- 2018-10-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03140631. Inclusion in this directory is not an endorsement.